Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients
Authors:
- Trevor S JohnstonTJTrevor S Johnston
- Camille HageCHCamille Hage
- Aura T AbedonAAAura T Abedon
- Jennifer L AlejoJAJennifer L Alejo
- Yolanda EbyYEYolanda Eby
- Dorry L SegevDSDorry L Segev
- Aaron A R TobianATAaron A R Tobian
- Andrea L CoxACAndrea L Cox
- William A WerbelWWWilliam A Werbel
- Andrew H KarabaAKAndrew H Karaba
- 2 July 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 79 (3) , 652-655
Abstract
Durability of variant neutralization in solid organ transplant recipients following Omicron-containing boosters is unknown. We report wane in XBB.1.5 neutralization by 3 months following a first bivalent booster, improved by a second booster; hybrid immunity improved peak, and duration of neutralization. Boosting at 3 to 6 months appears necessary to maintain neutralization.Keywords
Funding Information
- Ben-Dov family
- Trokhan Patterson family
- National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK007713)
- National Institute of Allergy and Infectious Diseases (K24AI144954, U01AI138897, 3U01AI138897-04S1, K08AI156021, K23AI157893)
- National Cancer Institute (U54CA260492)
- NIH
This publication has 12 references indexed in Scilit:
- Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patientsThe Lancet Infectious Diseases, 2023
- Omicron BA.4/5 Neutralization and T-Cell Responses in Organ Transplant Recipients After Booster Messenger RNA Vaccine: A Multicenter Cohort StudyClinical Infectious Diseases, 2023
- Analysis of Previous Infection, Vaccinations, and Anti–SARS-CoV-2 Antibody Titers and Protection Against Infection With the SARS-CoV-2 Omicron BA.5 VariantJAMA Network Open, 2023
- Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipientsAmerican Journal of Transplantation, 2023
- Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipientsAmerican Journal of Transplantation, 2023
- A Bivalent Omicron-Containing Booster Vaccine against Covid-19New England Journal of Medicine, 2022
- Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ TransplantJAMA Network Open, 2022
- A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipientsAmerican Journal of Transplantation, 2022
- Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)Clinical Infectious Diseases, 2022
- Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant RecipientsTransplantation, 2021